News Headlines

  1. Faster Time To Market: Rottendorf Pharma And Corealis Pharma Offer Seamless OSD Development And Manufacturing 2/11/2026

    Rottendorf Pharma, a globally leading CDMO with broad oral solid dosage (OSD) development, scale-up and manufacturing capabilities across the product lifecycle, and Corealis Pharma, a North American specialist in early-stage oral solid dosage (OSD) development and Phase I and II clinical supply, have expanded their service offering through a strategic partnership.

  2. FUJIFILM Biotechnologies Unveils Biomanufacturing And Process Development Expansion In The United Kingdom 2/11/2026

    FUJIFILM Biotechnologies, a world leading contract development and manufacturing organisation (CDMO) for biologics, vaccines, and advanced therapies, celebrated the grand opening of its expanded site in Teesside, UK, today.

  3. OneSource-Hikma Partnership Secures Approval To Commercialise Generic Version Of Ozempic In Saudi Arab 2/11/2026

    OneSource Speciality Pharma Limited today announced it has received Saudi Food and Drug Authority (SFDA) approval of its generic Ozempic (semaglutide) in Saudi Arabia, clearing the path for commercialsing the product with Hikma Pharmaceuticals PLC(Hikma) as their exclusive commercialisation partner for the Middle East and North Africa (MENA).

  4. Made Scientific And Streamline Bio Launch Exclusive Early Adopter Program To Advance AI-Driven Robotic Automation For Cell Therapy Manufacturing 2/10/2026

    Made Scientific, a leading clinical- and commercial-enabling cell therapy contract development and manufacturing organization (CDMO), and Streamline Bio, Inc., a next-generation autonomous robotics company transforming biomanufacturing with AI-driven precision robotics, today announced the launch of an exclusive Early Adopter and Design Partner Program.

  5. Lotus Pharmaceutical Becomes Commercialization Partner For Formycon's Keytruda Biosimilar Candidate FYB206 Across Major Parts Of The Asia-Pacific Region 2/10/2026

    Formycon AG and Lotus Pharmaceutical (“Lotus”) today announced the conclusion of an exclusive license agreement for Formycon’s Keytruda (1) biosimilar candidate FYB206 (Pembrolizumab).

  6. Kincell Bio Announces Partnership With RegCell To Advance Treg Cell Therapies Into Clinical Trials For Autoimmune Diseases 2/10/2026

    Kincell Bio, a leading U.S. cell therapy contract development and manufacturing organization (CDMO), today announced a new collaboration with RegCell, a biotechnology company developing first‑in‑class immune tolerance platform based on epigenetically reprogrammed regulatory T cells (Tregs).

  7. Trenchant BioSystems And Invetech Group Sign LOI To Form Strategic Alliance To Develop Fully Automated CGT Manufacturing Solution 2/10/2026

    Trenchant BioSystems Inc., the CGT manufacturing platform developer for gene-modified cells, and Invetech, a global leader in solving complex manufacturing and product development challenges in the advanced therapies and diagnostics markets, today announce the signing of a non-binding Letter or Intent (“LOI”) to form a strategic alliance to kickstart the development of Trenchant BioSystems’ AutoCell automated cell and gene therapy manufacturing platform from semi-automated Alpha prototype to a fully-automated commercial product.

  8. AsymBio Establishes Integrated Technology Platforms Spanning The Full Biopharmaceutical Development Lifecycle 2/10/2026

    AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), announced that it has established integrated technology platforms spanning the full biopharmaceutical development lifecycle. Through its end-to-end service capabilities, the company provides streamlined, integrated workflows from early development to commercial manufacturing.

  9. Kashiv BioSciences And Intas Pharmaceuticals Sign An Exclusive Licensing And Supply Agreement For Complex Peptide Product In Europe, The UK & India 2/9/2026

    Kashiv BioSciences, LLC (“Kashiv”) a vertically integrated biopharmaceutical company, today announced that it has entered into an exclusive licensing and supply agreement with Intas Pharmaceuticals Ltd (“Intas”), a leading multinational pharmaceutical company.

  10. Quantoom Biosciences Appoints Soter Bio As Exclusive North America RNA CDMO For RUO And GMP Manufacturing 2/9/2026

    Quantoom Biosciences, a leader in integrated RNA-LNP manufacturing technologies, today announced Soter Bio as its exclusive RNA Contract Development and Manufacturing Organization (CDMO) for both Research Use Only (RUO) and GMP manufacturing across North America, including the United States, Canada, and Mexico.